[Shin-Min Joon, Edaily Reporter] Huons announces price reduction of smart insulin pen to improve diabetes patients’ accessibility to care.

Huons’ smart insulin pen DIA:CONN P8. (Image=Huons)

Huons announced on October 27 that it will reduce the domestic retail price of its smart insulin pen DIA:CONN P8, which has demonstrated blood glucose improvement effects through local clinical research, by 31% to enhance treatment accessibility for diabetes patients.

Starting November 1, customers purchasing the DIA:CONN P8 individually through HU:ON Diabetes Care official website will be able to buy it at 380,000 won, down 31% from the previous price of 550,000 won.

Huons explained that this decision on price reduction was made to allow more diabetes patients to experience the latest digital blood glucose management solutions. The price reduction is also expected to help reduce the financial burden for type 2 diabetes patients and some type 1 diabetes patients who are not eligible for reimbursement benefits provided by National Health Insurance (NHI).

DIA:CONN P8 is the first stage 4 smart insulin pen to be launched in Korea. It automatically records insulin injection dosage, time, and injection site, allowing users to manage their data via a dedicated smartphone app.

DIA:CONN P8 is also equipped with a bolus insulin calculation feature linked with Continuous Glucose Monitoring (CGM) devices and enables precise micro-dosing adjustments at 0.1 unit increments. These capabilities allow patients to administer insulin in a more precise and safer manner. Such advanced features enhance treatment convenience, help reduce the risk of hypoglycemia, and support stability in blood glucose control.

DIA:CONN P8’s effectiveness and benefits for glycemic control in a real world setting have recently been evaluated through a clinical study.

According to the clinical study result published in the September issue of Diabetes & Metabolism Journal (DMJ), DIA:CONN P8 user group showed significantly greater Time In Range (TIR 70-180mg/dL) by 11% than the traditional insulin pen (TIP) user group despite receiving an average of 3.4 hours of training and education which was less than the TIP group’s 4.2 hours.

Furthermore Time Below Range (%TBR <70 mg/dL) and Glycemic Risk Index (GRI) of hyperglycemia and hypoglycemia were significantly greater in the DIA:CONN P8 group by 11.0%, -18.2, respectively.

Huons’ CEO Song Soo young said “This price adjustment aims to make our smart insulin pen more accessible to diabetes patients at a more reasonable cost. Huons is committed to expanding patient-centered accessibility and providing innovative diabetes management solutions to support patients in their daily care.”